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Background. Glioblastoma (GBM) is the most common primary brain tumor in adults, with a dismal prognosis. Treatment is ham-
pered by GBM’s unique biology, including differential cell response to therapy. Although several mitochondrial abnormalities have
been identified, how mitochondrial DNA (mtDNA) mutations contribute to GBM biology and therapeutic response remains poorly
described. We sought to determine the spectrum of functional complex III and IV mtDNA mutations in GBM.
Methods. The complete mitochondrial genomes of 10 GBM cell lines were obtained using next-generation sequencing and com-
bined with another set obtained from 32 GBM tissues. Three-dimensional structural mapping and analysis of all the nonsynon-
ymous mutations identified in complex III and IV proteins was then performed to investigate functional importance.
Results. Over 200 mutations were identified in the mtDNAs, including a significant proportion with very low mutational loads.
Twenty-five were nonsynonymous mutations in complex III and IV, 9 of which were predicted to be functional and affect mito-
chondrial respiratory chain activity. Most of the functional candidates were GBM specific and not found in the general population,
and 2 were present in the germ-line. Patient-specific maps reveal that 43% of tumors carry at least one functional candidate.
Conclusions. We reveal that the spectrum of GBM-associated mtDNA mutations is wider than previously thought, as well as novel
structural-functional links between specific mtDNA mutations, abnormal mitochondria, and the biology of GBM. These results
could provide tangible new prognostic indicators as well as targets with which to guide the development of patient-specific mito-
chondrially mediated chemotherapeutic approaches.
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Glioblastoma (GBM; World Health Organization grade IV) is the
most malignant and common primary brain tumor in adults.1
One percent of cases are diagnosed in patients younger than
20 years of age, 90% are primary de novo tumors, and 10%
are secondary tumors that develop from lower-grade gliomas.
GBM carries a dismal prognosis, with a median survival of just
14.6 months.2 Effective treatment is hampered by the unique
underlying heterogeneous biology of GBM, including differential
cell response to current therapies. Research over the last dec-
ade has revealed the existence of 6 main subgroups, classified
on the basis of cellular origin, anatomical compartment, and
various molecular alterations such as aberrations in phospha-
tase and tensin homolog/delta-like 3 (Drosophila), epidermal
growth factor receptor, neurofibromatosis type 1, platelet de-
rived growth factor receptor a/isocitrate dehydrogenase 1
(IDH1) gene expression, and more recently, H3 histone, family
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3A and IDH1 mutations, and transcriptomic signatures, high-
lighting that patient-specific profiles are linked to different
prognoses and/or responsiveness to therapies.3 – 5
Mitochondria are double-membrane organelles found in
most eukaryotic cells. The inner membrane hosts the multi-
subunit protein complexes of the oxidative phosphorylation
system (the mitochondrial respiratory chain [MRC] complexes
I–IV and ATP synthase or complex V) that produces most of
the ATP required for cell metabolism. Numerous other cellular
processes are also linked to MRC function, including the tricar-
boxylic acid cycle, reactive oxygen species (ROS) signaling,
generation of nicotinamide adenine dinucleotide phosphate,
mitochondrial membrane potential, and apoptosis.6 Mito-
chondrial DNA (mtDNA) is essential for producing 13 of the
core catalytic MRC protein subunits. Consequently, mtDNA
mutations often cause defects in the MRC, which in turn
have dramatic and multiple consequences for the cell.
Although GBM cells contain several mitochondrial abnor-
malities compared with normal brain cells,7 – 9 and mtDNA mu-
tations are proposed to be at the heart of the mitochondrial
abnormalities observed in cancers,10 patient-specific profiles
and functional roles of mtDNA mutations found in gliomas8,11–13
are poorly described. Confounding issues include the analyses of in-
complete genomes, inadequate ascertainment of mutation loads,
and/or the difficulties associated with proving direct links between
mtDNA mutation and phenotype.
Only a proportion of the multiple mtDNA molecules resident
in a cell or tissue will be mutated (heteroplasmy), influencing
whether the mutation exerts a functional effect. In the absence
of genetic transformation methods for the mammalian
mtDNA, the usual way of proving a link is to demonstrate a cor-
responding biochemical defect in affected tissue. However, it is
not practical to do this for every mutation, and more than one
nuclear or mitochondrial mutation may be present, further
confounding the interpretation.
Recently, we have demonstrated that 3D structural analy-
sis of mitochondrial proteins in silico, which takes into account
the bigenomic, quaternary structural organization of the MRC,
can be used to reveal detailed mechanistic insights into the
functional role of mutations in complex III and IV mtDNA
genes.14
In this study, we used deep sequencing to increase the num-
ber of entire primary GBM mtDNAs available and to highlight
the current known spectrum and heteroplasmies of GBM-
associated mutations of complex III and IV mtDNA genes.
Finally, we applied 3D structural analysis to the mutations to
predict their functional significance and reveal insights into
how they could contribute to the mitochondrial dysfunction
observed in gliomas and individual responses to mitochondri-
ally mediated chemotherapy.
Materials and Methods
All reagents, materials, and equipment were purchased from
Sigma-Aldrich, unless stated otherwise.
Patients and Samples
Set A consisted of new mitochondrial mutation data generated
from: 7 human biopsy-derived primary adult GBM cell lines and
1 matched blood sample, which were obtained from patients
from Kings College Hospital, London, under ethics permission
(REC reference number: 11/SC/0048); 2 primary pediatric GBM
cell lines obtained from other laboratories; 1 commercial pri-
mary adult GBM tumor cell line; and finally, 1 commercial non-
neoplastic adult astrocyte cell line (Supplementary Table S1).
Details of the cell culture techniques are described in the
Supplementary Materials and Methods. Set B consisted of
mitochondrial mutational data provided by whole-genome
sequencing of 32 primary adult GBM biopsies, each with
a matched blood sample, gathered by various centers on
behalf of The Cancer Genome Atlas network (Supplementary
Table S2).15 – 17
Whole Mitochondrial Genome Sequence Generation
Whole mitochondrial genome libraries were generated from
long PCR amplicons to avoid contaminating nuclear pseudo-
genes (Set A).18,19,20 Whole-exome or whole-genome libraries
were generated from total DNA (Set B).16 Set A libraries were
sequenced on an Illumina MiSeq,18 while the whole-exome or
whole-genome libraries were sequenced on an Illumina HiSeq
2000 or GA-IIX or Illumina GAII or HiSeq, respectively.16 Library
preparation and sequencing are described in detail in the
Supplementary Materials and Methods.
Assembly, Mutation Identification, and Heteroplasmy
Quantification
Set A and B reads were aligned using the Burrows–Wheeler
Aligner,21,23 and alignments were processed using GATK Unified
Genotyper24,25 (Set A) and ANNOVAR15,26 (Set B) to identify mu-
tations and calculate heteroplasmy. More details on Set A and B
mutational data generation are given in the Supplementary
Materials and Methods.
3D Structural Analysis
To obtain a more comprehensive interpretation, complex III
and IV mitochondrial mutational data from Set A and B
mtDNAs were combined for the subsequent functional pre-
diction and statistical analysis. The functional significance
of all nonsynonymous mitochondrial mutations in complex
III and IV proteins was then predicted using the 3D structural
analysis method previously developed and validated on mu-
tations associated with a broad range of human diseases, in-
cluding cancer.14 Briefly, based on location in the sequence
alignments, the mutations were mapped onto highly homol-
ogous bovine complex III and IV structures. Then, following
the detailed analysis of the location, relative to important
catalytic and/or interaction surfaces, mutations were placed
into 1 of 5 structural classes: (i) frameshift, (ii) active site, (iii)
binding pocket, (iv) protein interaction region, and (v) non-
functional (Supplementary Figs. S2 and S3). In addition, li-
gand docking analysis was performed on the mutation
F18L to determine its effect on ubiquinone binding. Further
details on the 3D structural modeling (including ligand dock-
ing analysis) are provided in the Supplementary Materials and
Methods.
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Statistical Analyses
As the prevalences and heteroplasmies of individual mutations
were varied, we used K-means and hierarchical (unweighted
pair-group average method29) cluster analyses to determine
the similarity of the mutations. The similarity metric (distance
measure) used by the K-means module was unscaled Euclide-
an distance. The data matrix used to determine similarity of
mutations was “3 variables×130 cases,” where the 3 variables
were (i) prevalence of each mutation in the GBM cohort (%GBM),
(ii) prevalence of each mutation in the general population
(%HmtDB), and (iii) heteroplasmy level of each mutation
(%Het), and the 130 cases were the number of nonsynonymous
and synonymous complex III and IV mutations found in the
combined (Set A+B) mtDNAs. ANOVAs were used to make sure
the clusters were statistically different. All analyses were per-
formed using Statistica 10 for Windows (Statsoft UK). The
HmtDB contains over 16 000 mitogenomic sequences obtained
from the tissues of normal, healthy subjects (%HmtDB27,28).
Results
New Deep Coverage Mitochondrial Genomes Permit
the Quantification of Heteroplasmy
We obtained 10 complete GBM cell line mtDNAs using long PCR
and next-generation sequencing (Set A). The size of all 10
mtDNAs was similar to the revised Cambridge Reference
Sequence (rCRS, NC_01292022), that is, 16 569 bp (Supplemen-
tary Table S4), and on average, the mitochondrial genomes
were assembled from 2.6 million reads (Supplementary
Table S4). The mean read lengths were 147+1 nucleotides.
The total number of reads with Q-score of 20 or above contrib-
uting to the assembled sequences was on average 97%+1
with a mean depth of coverage over the entire mitochondrial
genome of 22 695+5838 (Supplementary Table S4), provid-
ing the 250 reads with a minimal Q-score of at least 30 for
mutation detection and heteroplasmy determination. The
mean depth of coverage at mutation sites for Set B mtDNAs
was.5600.15 All new mtDNAs generated have been submitted
to GenBank with the following accession numbers (KJ735668-
KJ735679).
Germ-line Mutations and Heteroplasmy Are Key Features
A key question is whether mutations associated with GBM are
genetically inherited events (germ-line) or sporadic somatic
(non-germ-line) events. Analysis of a subset of 33 GBM samples
with corresponding matched bloods in the combined cohort al-
lowed us to determine whether the mutations were germ-line
or somatic. Set A mtDNAs (n¼ 10) contained 193 mutations
relative to the rCRS, whereas Set B (n¼ 32) contained 174 mu-
tations (Fig. 1A), and the average heteroplasmy of Set A
mtDNAs was lower than Set B (60%+39 vs 97%+9, respec-
tively; Fig. 1B and D). The differences between the datasets
were also evident at the individual patient level, where the
new data display .4-fold increase in the average number of
mutations observed per sample (Set A was 52+13 vs 12+6
in Set B; Fig. 1C). The ratio of germ-line to somatic mutations
is roughly consistent between the datasets (21:1 for Set A
and 35:1 for Set B), although this is 2–2.5-fold higher
than that previously documented for GBM studies that have fo-
cused on nuclear DNA.16
Twenty-five mutations that cause nonsynonymous amino
acid substitutions in complex III and IV proteins were found
in the combined GBM mtDNA dataset (Set A+ B; Table 1).
Thirty-two percent (8/25) have no known disease association
(Set A: C9469T, T9252C, A6692del, C6237A, T15479C, A15326G,
G15048A, and C14766T); 40% (10/25) were observed in GBM
previously (Set B: A15218G, T15453C, G15500A, T15693C,
A15758G, G6267A, G6619A, G9655A, A9667G, and G9966A);
16% (4/25) were found in both Sets A and B at very similar het-
eroplasmy despite the differences in sample types and meth-
odologies used to obtain the mutational data in each case
(A14793G, T14798C, C15452A, and G9477A); and 56% of the
mutations (14/25) had other disease associations (A14793G,
T14798C, A15218G, G15257A, C15452A, T15693C, A15758G,
G15803A, G6267A, G9300A, G9477A, G9655A, A9667G, and
G9966A) (Supplementary Table S5). The ratio of nonsynonymous
germ-line to somatic mutations was 8:1, lower than that de-
termined for all the different mutation types combined.
Nine Functional Mutations Identified
Following the identification of GBM-associated mutations, and
importantly their mutational load within tumor cells, we sought
to determine their functional significance. We predicted that 9
mutations have significant functional impact at the level of
protein structural changes, while the remaining 16 are likely
to be nonfunctional (Table 1). Among the mutations classified
as functional, 1 caused a frameshift in the triplet code (class 1),
3 occurred in active site regions (class 2), 1 occurred in a
substrate/product binding pocket (class 3), and 4 occurred
in protein interaction regions (class 4). As expected, no func-
tional mutations were present in the non-neoplastic astrocyte
control.
Functional Mutations Can Be Either Somatic or Germ-line
Among the subset of functional candidates, 2 in mitochondri-
ally encoded (MT) cytochrome b (CYB) were germ-line (T14798C
and G15500A), while 2 in MT–cytochrome c oxidase (CO) 1 and
MT-CO3 were somatic (G6619A and G9655A, respectively).
Contrary to what has been observed in some cancers, such as
gastric cancer,30 our results suggest that both inherited and
spontaneous mtDNA mutations could play a role in mitochon-
drial dysfunction and the biology of GBM.
A Global Structural Map
All nonsynonymous amino acid substitutions in complex III
and IV genes were mapped onto their corresponding structural
homologs (Fig. 2). These structures, together with decades of
associated systematic biochemical analysis in the field, provide
a window into the functional consequences of individual muta-
tions. To our knowledge this is the first visual compendium of
mutation sites found within the MRC proteins of GBM patients
and it reveals a non-uniform distribution. Although many
mitochondrial-encoded subunits act as hotspots for functional
mutations, subunit MT-CO2 remains mutation free.
Lloyd et al.: Functional mitochondrial mutations in GBM
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Patient-Specific Structural Maps
A powerful aspect of this method is the ability to easily produce
maps on an individual patient basis. Structural maps (relative to
the non-neoplastic astrocyte control) of the functional mito-
chondrial mutations (F18L, G101D, L236P, F245L, D252N,
G239D, W16R, and S150N) present in individual patients were
generated (Fig. 3). Altogether 16 of the 42 GBM samples (38%)
carried a single functional mutation, just 2 of the 42 (5%) car-
ried 2 functional mutations, while 24 GBM samples (57%) did
not carry a functional mutation in either complex III or complex
IV. This does not preclude the possibility that mutations in other
regions of the MRC, such as in complex I or V, may be contrib-
uting to the pathology and/or drug sensitivity of GBM samples.
Currently, the lack of close structural homologs to human com-
plexes I and V limits informative mapping studies.
Cluster Analysis Identifies 2 Distinct Groups
Across the 42 GBM patients, high variability was observed in the
prevalence of individual mutations (2%–30%). A comparison
with prevalence in a large group of samples from over 16 000
subjects from the general population revealed that several mu-
tations were absent, while others were present in as much as
10% of the general population. The heteroplasmy revealed
a more dramatic range from as little as 8% for some mutations
to as much as 100% for others (Table 1).
Two distinct groups of mutation were identified by integrat-
ing both the hierarchical (unweighted pair-group method with
arithmetic mean) and nonhierarchical (K-means) outputs with
the functional predictions (Fig. 4, Table 1):
(1) Functional, GBM: A small group of almost exclusively func-
tional mutations (5 of 6, 86%) found in single patients
(2.38%+0.00) but 39-fold less frequently in the general
human population (0.06%+0.16), with low mutational
loads (15.52%+10.02)
(2) Nonfunctional, mixed: A large group of almost exclusively
nonfunctional mutations (3 of 124, 2.42%) found in multi-
ple patients (13.94%+11.60) and multiple subjects in the
general human population (3.42%+4.04), with very high
heteroplasmy levels (98.13+3.17%).
Fig. 1. Abundance and heteroplasmy of mutations in GBM samples in 10 GBM biopsy–derived cell cultures (Set A, black bars) and 32 GBM biopsy
tissues (Set B, gray bars). Combined (A and B, respectively) and in individual (C and D, respectively) profiles.
Lloyd et al.: Functional mitochondrial mutations in GBM
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Table 1. Structural classification and functional prediction, presence in control astrocytes, heritability, heteroplasmy level, and prevalence of mutations in the mtDNA complex III and IV
genes identified in GBM
Human Subunit
(gene)
Human Residue
(nucleotide)
%GBM* %HmtDB** (tissue) %Het+SD K-means
Group
Heritability*** Presence in
Non-neoplastic
Astrocytes
Structural/
Functional
Class
3D Modeling
Prediction
MT-CYB (mt-cyb) T7I (C14766T) 14.29 0 98.25+3.14 2 Inherited Yes 0 Nonfunctional
H16R (A14793G) 4.76 2.32 (blood) 98.7+1.27 2 Inherited No 0 Nonfunctional
F18L (T14798C) 30.95 8.66 (blood, buccal) 98.98+1.71 2 Inherited No 3 Functional
G101D (G15048A) 2.38 0 17 1 ND No 2 Functional
T158A (A15218G) 2.38 1.90 (blood, buccal) 97.9 2 Inherited No 0 Nonfunctional
D171N (G15257A) 2.38 1.43 (blood, buccal) 99.6 2 ND No 0 Nonfunctional
T194A (A15326G) 23.81 0 98.80+0.29 2 Inherited Yes 0 Nonfunctional
L236I (C15452A) 30.95 10.18 (blood, buccal,
bone)
96.02+3.76 2 Inherited Yes 0 Nonfunctional
L236P (T15453C) 2.38 0.03 (blood, buccal) 98.5 2 Inherited No 4 Functional
F245L (T15479C) 2.38 0.38 (blood) 16.4 1 ND No 4 Functional
D252N (G15500A) 2.38 0 4.99 1 Inherited No 2 Functional
M316T (T15693C) 2.38 1.25 (blood) 99.8 2 Inherited No 0 Nonfunctional
I338V (A15758G) 2.38 0.75 (blood, buccal) 99.8 2 Inherited No 0 Nonfunctional
V353M (G15803A) 2.38 0.1 (blood) 93.6 2 ND No 0 Nonfunctional
MT-CO1
(mt-co1)
L112M (C6237A) 2.38 0.08 (ns) 99.6 2 ND No 0 Nonfunctional
A122T (G6267A) 2.38 0.16 (blood) 99.9 2 Inherited No 0 Nonfunctional
G239D (G6619A) 2.38 0 33.7 1 Somatic No 2 Functional
M271Ter (A6692del) 2.38 ND 8 ND No 1 Functional
MT-CO3
(mt-co3)
W16R (T9252C) 2.38 0 8.6 1 ND No 4 Functional
A32T (G9300A) 2.38 0.47 (blood) 100 2 ND No 0 Nonfunctional
T88I (C9469T) 4.76 0.06 (ns) 99.2 2 Inherited No 0 Nonfunctional
V91I (G9477A) 4.76 4.41 (blood) 98.55+1.45 2 Inherited No 0 Nonfunctional
S150N (G9655A) 2.38 0.01 (ns) 73.8 2 Somatic No 4 Functional
N154S (A9667G) 2.38 0.75 (blood) 92.6 2 Inherited No 0 Nonfunctional
V254I (G9966A) 2.38 0.67 (blood, buccal) 96.8 2 Inherited No 0 Nonfunctional
Abbreviations: ND, not determined; ns, not specified; K-means group—mutations were stratified into 2 groups based on 3 variables: %GBM¼ prevalence of mutations in the GBM cohort,
%HmtDB ¼ prevalence of mutations found in the human mitochondrial database, and %Het ¼ heteroplasmy.
* n¼ 42. **n¼.16 000. ***Mutations listed as “inherited” were found in both tumor and matched blood samples and are therefore likely to occur in the germ-line, while those listed as
“somatic” were found in the tumor samples only and are therefore likely to be spontaneous events.
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Post-hoc ANOVA comparisons confirmed that all 3 variables
differed significantly between the 2 groups: prevalence in all
the GBM samples tested (%GBM, P, .02), prevalence in the ge-
neral population (%HmtDB, P, .04), and heteroplasmy (%Het,
P , .0000001).
New Mechanistic Insights
We employed 3D structural analysis and docking studies to
predict the effects of mutations on MRC activity and ligand
binding, respectively. In order to demonstrate the wide spec-
trum of functional consequences that can arise from single
mtDNA point mutations, we have provided graphical examples
of 3 scenarios that include the dramatic loss of a large portion
of protein subunits through to extremely subtle atomic
rearrangements.
Figure 5A and B depict the structural consequence of the
frameshift mutation A6692del on complex IV. In the wild
type, MT-CO1 is the central and major subunit of complex IV,
the terminal enzyme of the MRC that catalyzes electron trans-
fer from cytochrome c to oxygen, conserving the released
energy as coupled transmembrane proton transfers (Fig. 5A).
The deletion of a single adenine nucleotide at position 6692
of the mitochondrial genome results in a change of 5 amino
acids and ultimately a stop codon being introduced at position
271 of MT-CO1. This results in the deletion of 47% of the
subunit and occurs in both halves of the dimeric complex
(Fig. 5B). It is likely that the truncated MT-CO1 (Fig. 5B) will
not have sufficient surface area to form stabilizing contacts
with the redox groups (heme a, heme a3, and CuB) or the
other subunits found within complex IV, whether mitochondrial
(MT-CO2 and MT-CO3) or nuclear (COX4I1, COX5B, COX6A,
COX7C, COX7A, COX6B, and COX6C), impairing complex IV
assembly. This loss in quaternary structure will further compro-
mise the activity of additional MRC complexes, as associations
among complexes IV, I, and III have been demonstrated to be
vital for MRC function, assembly, and stability.31
G15500A results in the amino acid change D252N in MT-CYB
(Fig. 5C and D). MT-CYB is the central subunit of complex III, the
middle enzyme of the MRC that couples the transfer of elec-
trons from ubihydroquinone to cytochrome c while translocat-
ing protons across the inner mitochondrial membrane (Fig. S4).
On the basis of atomic structure, the D252 residue, conserved
in all metazoans, is proposed to be part of a proton exit route
from the catalytic site (Qo site) in complex III.
32 The D252 res-
idue occupies a key position within the Qo site, being in direct
contact with the external solvent in the intermembrane
space. In addition, an interaction has been proposed between
residues D252 and E272 via a complex network of water-
mediated hydrogen bonds. Although E272 has been proposed
to be a proton acceptor, more recent mutational analysis has
indicated that E272 may rather serve as a relay on the proton
Fig. 2. (A) Complexes III and (B) IV 3D crystallographic structural maps of GBM mitochondrial mutation sites. Functional sites (red spheres);
nonfunctional sites (blue spheres). Both complete dimeric complexes are depicted as ribbon models, with the mitochondrial-encoded MT-CYB
subunit colored as orange and MT-CO1, MT-CO2, and MT-CO3 colored as magenta, yellow, and cyan, respectively. Nuclear-encoded subunits
are colored in gray, and key functional sites, such as metalloprotein and substrate binding pockets, are annotated.
Lloyd et al.: Functional mitochondrial mutations in GBM
6 of 11 Neuro-Oncology
 at U
niversity of Portsm
outh Library on M
arch 9, 2015
http://neuro-oncology.oxfordjournals.org/
D
ow
nloaded from
 
exit pathway.33 Figure 5C depicts the position of D252 relative
to the Qo site and E272. In either case, whether a block in the
protein exit pathway directly or disruption of the mobile E272
relay mechanism, the loss of a protonable amino acid residue
in mutant D252N (Fig. 5D) is predicted to slow down the
movement of protons from the Qo site, reduce the electron
transfer rate, and thus compromise the activity of complex III.
T14798C, which results in an amino acid change F18L in
MT-CYB (Fig. 5E to H), is an example of a binding pocket muta-
tion and forms part of the ubiquinone (coenzyme Q) binding
Fig. 3. Functional mitochondrial mutation profiles of individual GBM biopsy–derived cell cultures (Set A) and GBM biopsy tissues (Set B). Samples
124, 152, 155, 744, 745, 827, 882, 1438, 1830, UP-015, and IN699 contained just F18L; sample SEBTA-008 contained just G101D; sample 188
contained just L236P; sample 1454 contained just D252N; SNB19 contained just W16R; and 742 contained just S150N. Sample UP-060 contained
F245L and A6692del (see Fig. 5), while 692 contained both F18L and G239D. Samples 145, 185, 208, 214, 648, 686, 786, 821, 828, 846, 861, 877,
878, 881, 1063, 1086, 1401, 1459, 1460, SEBTA-003, SEBTA-015, UP-019, UP-029, and KNS42 were essentially like the SC-1800 (non-neoplastic
astrocyte control) and contained no functional mutations (and so are not shown). The depth of coverage (DOC) used to calculate the percentage
heteroplasmy of the functional candidates is also indicated.
Lloyd et al.: Functional mitochondrial mutations in GBM
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site (Qi site) of complex III (Fig. S4). According to the structure
of the wild-type Qi site in complex III, ubiquinone interacts with
the buried heme in a “lock and key”-style enclosed environ-
ment (Fig. 5E). The pocket has evolved to make intimate con-
tacts to the ubiquinone to action binding, redox reaction, and
dissociation. In order to model the effect of GBM mutations
on binding, we first used an in silico docking approach with
the wild-type pocket and the natural substrate. We were able
to simulate the precise docking of ubiquinone as observed in
the crystal structure (Protein Data Bank identification [PDB ID]
1NTZ34) (Fig. 5F and Supplementary Fig. S5). We then modeled
the effect of mutation F18L on this interaction and revealed
that the structure of the binding cavity is opened up by the
loss of a bulky aromatic group leading to alternative ubiquinone
binding modes (Fig. 5G and H). It is likely that these additional
modes are non-optimal for the crucial balance of association
and dissociation following the redox event and are likely to
influence the activity of complex III.
Discussion
Despite significant advances in our understanding and treat-
ment of cancers, GBM patients have a very limited survival
and it is clear that current treatments are woefully inade-
quate. Our focus here was to identify and collate specific
mtDNA mutations that are likely to contribute to GBM develop-
ment, progression, and/or chemosensitivity. Our results reveal
that the spectrum of mtDNA mutations associated with GBM is
wider than previously thought and that individual patients
present a surprising diversity of mutational and heteroplasmy
profiles.
New Methods Yield Subtle Signatures
Numerous mtDNA mutations have been reported in a range of
brain tumor types,8,13,35 – 39 including GBM,8,11 – 13,15 although
many of these studies were incomplete, as they explored
small portions of the mtDNA or used nonquantitative sequenc-
ing methods of limited sensitivity (eg, Sanger sequencing). Con-
sequently, several potentially key mtDNA mutations have
almost certainly been missed and their heteroplasmies over-
looked, despite the latter being an important determinant of
whether an mtDNA mutation exerts a phenotype.
Using 3D structural analysis, we predicted that 9 nonsynon-
ymous complex III/IV mutations are functional, occurring
mainly in MT-CYB. This finding is consistent with a previous ob-
servation that mutations associated with neuropathies tend to
occur preferentially in MT-CYB. In the only other previous study
where mutations were mapped across a wide-disease cohort,
cancer mutations were found solely in complex IV. It is intrigu-
ing that GBM shares a signature more closely aligned with neu-
ropathies, rather than cancers per se. In this way GBM has an
atypical profile compared with other cancers, although this
may reflect the neural origins of the cells.14
Unexpectedly, 2 clearly defined subgroups of brain tumor–
associated mutation were identified using a combination of
statistical and structural data. Such groupings have not been
previously recognized. It is generally thought that mutations
that promote cancer will be selected more frequently than neu-
tral mutations,40 so the mutations in subgroup 1 (hetero-
plasmy)—G101D (17%), F245L (16%), D252N (5%), G239D
(34%), and W16R (9%)—are of particular interest given that
they are more prevalent in GBM samples compared with
those obtained from healthy individuals and are predicted to
be functional. However, it is of note that 90% of the control
mtDNAs were obtained from blood samples. Given that patho-
genic mutations can be lost in blood over time,41 the possibility
that potentially functional mtDNA mutations identified in GBM
could be found in less proliferative tissues of controls cannot be
ruled out and warrants further investigation.
MtDNA Mutations as Novel Diagnostic and Therapeutic
Targets
The extent to which mtDNA mutations contribute to tumor ag-
gression may depend on their specific impact on MRC activi-
ty.36,42 For example, mutations that mildly affect the activity
of the MRC and stimulate ROS production36 have been shown
to promote hypoxia-inducible factor 1a (HIF1-a) stabilization/
hypoxic adaptation, leading to a more aggressive phenotype.42
In contrast, mutations that severely affect the activity of the
MRC and abrogate ROS production have been shown to prevent
HIF1-a stabilization/hypoxic adaptation and increase chromo-
somal stability, leading to a less aggressive tumor pheno-
type.36,43,44 Although severe complex IV deficiency has been
linked to a less aggressive phenotype in GBM,45 whether this
was a result of an underlying mutation in mtDNA was not
investigated.
In this study, we identify a single germ-line point mutation,
T14798C, that is present in one-third of the GBM patients test-
ed. This is a significant finding because not only is this mutation
predicted to alter the binding of the natural complex III
Fig. 4. Integration of hierarchical and nonhierarchical cluster and
structural analyses of complex III and IV GBM-associated mtDNA
mutations reveals 2 naturally occurring subgroups using the following
variables: prevalence of each mutation in GBM; prevalence of each
mutation in normal, healthy subjects; and heteroplasmy level. Group
1 mutations are significantly less frequent in healthy compared with
GBM samples but are almost exclusively functional. Group 2
mutations occur in multiple healthy and GBM samples but are mostly
nonfunctional.
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Fig. 5. Structural consequences of 3 classes of functional mutation present in GBM complex III and IV mitochondrial proteins (colored as in Fig. 2).
Frameshift mutation. (A) Wild-type (M271) residue in MT-CO1 is rendered as a space-filling model (light pink), highlighting its central position within
each monomer. (B) The mutant A6692del (M271Ter) results in deletion of .47% of the MT-CO1 polypeptide chain, disrupting the interaction of
multiple subunits that surround MT-CO1. Active site mutation. (C) Wild-type (D252) residue within the MT-CYB complex III Qo site. (D) The mutant
(N252) may affect the passage of protons from the hydroxyquinone (blue) bound at the Qo site to the solvent phase. Residue E272 is shown in the 2
alternate conformations observed in x-ray crystal structures with the stigmatellin-inhibited complex (PDB ID 1KB950) (cyan) and in the HHDBT
(5-n-heptyl-6-hydroxy-4, 7-dioxobenzothiazole)-inhibited complex (PDB ID 1P8432) (orange) and heme bL. The quinol binding site is inferred
from the inhibitors binding site. Binding pocket mutation in complex III Qi site. (E) The wild-type Qi-site pocket is shown as a surface
representation with the deeply buried heme group and bound ubiquinone (PDB ID 1NTZ34) (blue). (F) The results from in silico docking studies
confirm that the predicted hydroxyquinone position (yellow) corresponds closely to that observed in the crystal structure. (G) An extra cavity is
shown where the F18L GBM mutation (red) opens up the binding pocket. (H) The hydroxyquinone is observed to occupy additional binding sites
(white) that are not possible in the wild-type protein due to steric constraints provided by the aromatic F18 residue. Since this highly conserved
pocket is tailored precisely for hydroxyubiquinone binding, such a change is likely to interfere with its association/dissociation and ultimately
efficient electron transfer from heme bH.
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substrate ubiquinone and thus the activity of complex III and
ROS levels (complex III is a major site of ROS production), but
it could alter the binding of Qi site inhibitors. Indeed, some of
the most effective respiratory inhibitors, such as antimycin
and stigmatellin, have been found to act directly at the ubiqui-
none Qi and Qo sites, respectively. There is strong biochemical
and structural evidence that explains the molecular basis for
the mutations at these sites that confer resistance to these
compounds.34,46 This discovery raises the possibility that
complex III inhibitors could be used to trigger mitochondrially
mediated apoptosis in some subgroups of GBM patients more
effectively than others. Similarly, such information also has
the potential to inform the clinician which drugs are likely or
unlikely to be effective given a particular mtDNA genetic
background.
Predisposing Elements or Triggers of Tumor Formation?
Some mutations occur in the germ-line prior to tumor initiation
and act as predisposing elements to neoplastic transformation
but do not necessarily cause tumors independently. Other mu-
tations occur somatically and can trigger tumor formation ei-
ther alone or in combination with a predisposing element.
Although both somatic and germ-line mtDNA mutations have
been documented in a range of brain tumor types, studies in-
vestigating the heritability of mtDNA mutations associated with
GBM are generally lacking. Gliomas are known to aggregate in
some families, suggesting an inheritable genetic basis. Most of
these familial cases are associated with well-known tumor syn-
dromes (eg, neurofibromatosis, Li–Fraumeni). The discovery
that 2 of the functional complex III mutations were germ-line
reveals a potential genetic predisposition for a small proportion
of familial gliomas that occur in the absence of known syn-
dromes.47 – 49 Equally, the 2 functional complex IV mutations
identified as somatic are potential candidates for triggering gli-
oma formation. It remains to be shown whether these muta-
tions are predisposing elements or are sufficient to drive tumor
formation independently. In the absence of routine methods
for the genetic manipulation of mtDNA, deciphering the contri-
bution of single mtDNA mutations to gliomagenesis will require
the development of innovative new approaches.
If the proposed functional mtDNA mutations identified are
shown to contribute to gliomagenesis or correlate with key clin-
ical parameters, such as age at diagnosis, therapeutic re-
sponse, and survival outcome, this will have an impact on
how the main GBM subgroups, which currently focus mainly
on nuclear genome aberrancies, are treated in the future.
They may also provide new targets for the development of
mitochondrially mediated therapeutics. Thus future studies of
GBM should focus on exploring the role of these mitogenomic
elements in gliomagenesis and as indicators of prognosis and
drug sensitivity, which will become possible as novel models
are developed and as the size of the GBM cohorts with available
molecular (particularly mitogenomic) and clinical data grows.
Supplementary Material
Supplementary material is available at Neuro-Oncology Journal
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